

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
00 AUG -9 PM 5:34

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The Legislative Strategies Group			
2. Address <input type="checkbox"/> Check if different than previously reported 1001 Pennsylvania Avenue, N.W., Suite 760 North, Washington, D.C. 20004			
3. Principal Place of Business (if different from line 2) City: N.A. State/Zip (or Country)			
4. Contact Name Katherine Merritt	Telephone (202) 661-7060	E-mail (optional)	5. Senate ID # 43651-
7. Client Name <input type="checkbox"/> Self Novartis Corporation			6. House ID # 34137

8. TYPE OF REPORT Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)
 9. Check if this filing amends a previously filed version of this report
 10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ 40,000 <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇒ \$ _____ <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature *Larry E. Smith*
 Printed Name and Title Larry E. Smith, President AUG 10 2001

Registrant Name The Legislative Strategies Group Client Name Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues
Medical/Medicare device reimbursement
Privacy of Health Information

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives Health Care Financing Administration
U.S. Senate Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Martin B. Gold		<input type="checkbox"/>
Denise M. Henry		<input type="checkbox"/>
Larry E. Smith		<input type="checkbox"/>
Allison Giles		<input type="checkbox"/>
Steven M. Hilton, Esq.		<input type="checkbox"/>
G. David Mason		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____

Printed Name and Title Larry E. Smith, President August 9, 1999

Registrant Name The Legislative Strategies Group Client Name Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Health Care Issues

17. House(s) of Congress and Federal agencies contacted Check if None
U. S. House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Martin B. Gold		<input type="checkbox"/>
Denise M. Henry		<input type="checkbox"/>
Larry E. Smith		<input type="checkbox"/>
Allison Giles		<input type="checkbox"/>
Steven M. Hilton, Esq.		<input type="checkbox"/>
G. David Mason		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____

Printed Name and Title Larry E. Smith, President

Registrant Name The Legislative Strategies Group Client Name Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Clinical, laboratory and medical issues

17. House(s) of Congress and Federal agencies contacted

Check if None

U. S. House of Representatives

United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Martin B. Gold		<input type="checkbox"/>
Denise M. Henry		<input type="checkbox"/>
Larry E. Smith		<input type="checkbox"/>
Allison Giles		<input type="checkbox"/>
Steven M. Hilton, Esq.		<input type="checkbox"/>
G. David Mason		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____

Printed Name and Title Larry E. Smith, President

Page 4 of 5

Registrant Name The Legislative Strategies Group Client Name Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Drug packaging, labeling and other pharmacy issues

17. House(s) of Congress and Federal agencies contacted Check if None
U. S. House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Martin B. Gold		<input type="checkbox"/>
Denise M. Henry		<input type="checkbox"/>
Larry E. Smith		<input type="checkbox"/>
Allison Giles		<input type="checkbox"/>
Steven M. Hilton, Esq.		<input type="checkbox"/>
G. David Mason		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature
Printed Name and Title Larry E. Smith, President August 9, 2000